TAK
Takeda Pharmaceutical·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
High Gross Profit Margin
Significant Net Income Decline
High Cash/net Profit Ratio
Bullish Abandoned Baby
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TAK
Takeda Pharmaceutical Company Limited
The largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world
Pharmaceutical
01/12/1925
12/24/2018
New York Stock Exchange
47,455
03-31
Depository Receipts (Ordinary Shares)
1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668, Japan
Development of medicines for gastroenterology, oncology and neuroscience
Takeda Pharmaceutical Company Limited is a public company incorporated in Japan on January 12, 1925. The Company and its subsidiaries are a major global pharmaceutical group engaged in the research, development, manufacturing and marketing of pharmaceutical products, over-the-counter and quasi-pharmaceutical consumer products, and other healthcare products. Takeda's main pharmaceutical products include drugs in the following therapeutic areas: gastroenterology, oncology and neuroscience.
Company Financials
EPS
TAK has released its 2024 Q3 earnings. EPS was reported at 0.51, versus the expected 0, beating expectations. The chart below visualizes how TAK has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TAK has released its 2026 Q2 earnings report, with revenue of 7.52B, reflecting a YoY change of -8.40%, and net profit of -79.27M, showing a YoY change of -112.33%. The Sankey diagram below clearly presents TAK's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
